
    
      Key eligibility criteria include:

        -  Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative)
           treatment

        -  No use of hormone contraceptives or replacement therapy within 30 days prior to the
           diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior to
           starting the study)

        -  No prior or current use of any therapy to treat the current breast cancer.
    
  